( - )-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release

European Journal of Pharmacology

Volumn 421, Issue 3, 2001, Pages 181-189

  Shimazu, Seiichiro ^a   Takahata, Kazue ^a   Katsuki, Hiroshi ^b   Tsunekawa, Hiroko ^a   Tanigawa, Akie ^a   Yoneda, Fumio ^a   Knoll, Joseph ^c   Akaike, Akinori ^b  

^a Fujimoto Pharmaceutical Corporation   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

( ) Deprenyl; 6 Hydroxydopamine; ( ) BPAP HCl ( ) 1 (benzofuran 2 yl) 2 propylaminopentane hydrochloride; Catecholaminergic and serotoninergic activity enhancer; Parkinson's disease; Reserpine

Indexed keywords

1 (BENZOFURAN 2 YL) 2 PROPYLAMINOPENTANE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMANTADINE; APOMORPHINE; BENZOFURAN DERIVATIVE; OXIDOPAMINE; RESERPINE; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; LOCOMOTION; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PTOSIS; RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; AMANTADINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOFURANS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HABITUATION, PSYCHOPHYSIOLOGIC; MALE; MOTOR ACTIVITY; OXIDOPAMINE; RATS; RATS, WISTAR; RESERPINE; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

EID: 0035876074     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01040-8     Document Type: Article

References (40)

1. Biochemical substrates of mental disturbances in Parkinson's disease
2. The pathogenesis of Parkinson's disease: A new hypothesis
3. Zur biochemie des Parkinson-Syndroms des menschen: Einfluß der Monoaminoxidase-Hemmer-Therapie auf die konzentration des dopamins, noradrenalins und 5-Hydroxytryptamins im gehirn
4. Der L-3,4-Dioxyphenylalanin ( = DOPA)-Effekt bei der Parkinson-Akinese
5. Implications of combined treatment with "madopar" and L-deprenil in Parkinson's disease
6. Treatment of parkinsonism with bromocriptine
7. Monoamine-depleting drugs
8. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor
9. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat
10. A comparison of circling models for the detection of antiparkinson activity
11. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems
12. The neurobiological substrates of depression in Parkinson's disease: A hypothesis
13. Amphetamine-induced locomotor stereotypy in rats is reduced by a D1 but not a D2 antagonist
14. Locomotor stereotypy produced by dexbenzetimide and scopolamine is reduced by SKF 83566, not sulpride
15. Antiparkinsonian drugs and dopaminergic neostriatal mechanisms: Studies in rats with unilateral 6-hydroxydopamine ( = 6-OH-DA)-induced degeneration of the nigro-neostriatal DA pathway and quantitative recording of rotational behavior
16. The possible role of noradrenergic deficits in selected signs of Parkinson's disease
17. Lisuride in parkinsonism
18. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data?
19. Long-term sensitization of apomorphine-induced rotation behavior in rats with dopamine deafferentation or excitotoxin lesions of the striatum
20. ( - )Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain
21. Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: Rationale for prophylactic ( - )deprenyl (selegiline) medication
22. The pharmacology of 1-phenyl-2-propylaminopentane (PPAP), a deprenyl-derived new spectrum psychostimulant
23. ( - )Deprenyl and ( - )1-phenyl-2-propylaminopentane, [( - )PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons
24. High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers
25. Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain
26. ( - )1-(Benzofuran-2-yl)-2-propylaminopentane, [( - )BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain
27. Dopamine receptor supersensitivity
28. Strain differences to the effects of central acting drugs on Sidman avoidance response in Wistar and Fischer 344 rats
29. Effects of D1 and D2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine in mice
30. Depression in Parkinson's disease: A biochemical and organic viewpoint
31. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats
32. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats
33. Effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8- yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, on impaired learning and memory in animal models
34. Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment
35. Apomorphine in Parkinson's disease
36. Amantadine in the treatment of Parkinson's disease
37. On-off effects of dopamine receptor agonists in the hemi-parkinsonian rat
38. 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: The turning syndrome
39. Dopamine: Release from the brain in vivo by amantadine
40. Structure-activity studies leading to ( - )1-(benzofuran-2-yl)-2-propylaminopentane, [( - )BPAP], a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain